OBJECTIVES: To determine the preferable treatment scheme for breast cancer (BC) from the pharmacoeconomic perspective by the comparison of subcutaneous (SC) and intravenous (IV) administration. METHODS: The following pharmacoeconomic methods were used: cost-minimization analysis, budget impact analysis. RESULTS: For cost-minimization analysis the following costs were included: cost of testing on tumor expression of HER2, the main drug therapy, concomitant therapy (medical services and drugs), introduction, services provided by medical personnel and the conditions of administration (in case of hospitalization or outpatient). Total costs per 1 patient with BC for treatment course with trastuzumab for subcutaneous administration were 1 314 181 RUB/21 863 EUR and 1 503 716 RUB/25 016 EUR of trastuzumab for IV administration. Cost-minimization analysis revealed treatment change from trastuzumab for IV administration on trastuzumab for SC administration gave economy of 189 535 RUB/3 153 EUR per 1 patient for treatment course. According to budget impact analysis it was revealed that trastuzumab for SC administration allows to make economy of 175 508 955 RUB/2 919 796 EUR. CONCLUSIONS: During cost-minimization analysis it is determined that trastuzumab for IV allows to obtain economy compared with IV dosage form. Budget impact analysis reveals that change of BC treatment from trastuzumab for IV administration on trastuzumab for SC one give monetary economy.